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Available online 23 December 2015In lysosomal glycosphingolipid storage disorders, marked elevations in corresponding glycosphingoid
bases (lyso-glycosphingolipids) have been reported, such as galactosylsphingosine in Krabbe disease,
glucosylsphingosine in Gaucher disease and globotriaosylsphingosine in Fabry disease. Using LC–MS/MS,
we comparatively investigated the occurrence of abnormal lyso-glycosphingolipids in tissues and plasma
of mice with deﬁciencies in lysosomal α-galactosidase A, glucocerebrosidase and galactocerebrosidase.
The nature and speciﬁcity of lyso-glycosphingolipid abnormalities are reported and compared to that in
correspondingly more abundant N-acylated glycosphingolipids. Speciﬁc elevations in tissue and plasma
globotriaosylsphingosine were detected in α-galactosidase A-deﬁcient mice; glucosylsphingosine in
glucocerebrosidase-deﬁcient mice and galactosylsphingosine in galactocerebrosidase-deﬁcient animals. A
similar investigation was conducted for two mouse models of Niemann Pick type C (Npc1nih and Npc1-
nmf164), revealing signiﬁcant tissue elevation of several neutral glycosphingolipids and concomitant in-
creased plasma glucosylsphingosine. This latter ﬁnding was recapitulated by analysis of plasma of NPC
patients. The value of plasma glucosylsphingosine in biochemical conﬁrmation of the diagnosis of NPC is
discussed.
© 2016 Elsevier Inc. All rights reserved.Keywords:
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LC–MS/MS1. Introduction
The existence of glycosphingolipids (GSLs), membrane constituents
consisting of a ceramide core with attached (oligo)saccharides, was
demonstrated by Thudichum in the late 19th century through his
pioneering studies on the chemical composition of the brain [1]. During
the last century an increasing number of inherited disorders with
characteristic accumulation of speciﬁc GSLs were described. It was
later discovered that these glycosphingolipidoses result from inherited
impairments in lysosomal degradation of GSLs (reviewed in reference
[2]). In most cases the primary genetic defect concerns a lysosomalycosphingoid base; Lyso-Gb3,
; GlySph, glycosylsphingosine;
ry, Gorlaeus Laboratories, Room
herlands.
ts).glycosidase and examples of such enzymopathies are Tay-Sachs disease,
GM1 gangliosidosis, Sandhoff disease, Fabry disease (FD), Gaucher dis-
ease (GD) and Krabbe disease [2]. Intralysosomal GSL accumulation
may also arise secondarily as in the case of Niemann–Pick type C
(NPC), in which cholesterol export from lysosomes is primarily im-
paired due to inherited defects in the non-enzymatic proteins NPC1 or
NPC2 [3,4]. As ﬁrstly demonstrated for Krabbe disease, lysosomal stor-
age of GSL can be accompanied by elevations in the corresponding
glycosphingoid base (lyso-GSL) lacking the fatty acid, normally linked
via an amide-bond to the sphingosine moiety [5]. For a schematic over-
view of relevant GSL metabolism see Supplemental Fig. 1. Due to difﬁ-
culties in their quantitative detection, lyso-GSLs received relatively
little attention for a long time. The recent use of LC–MS/MS in quantiﬁ-
cation of lyso-GSLs has revolutionized their analysis and led to a rapidly
increasing amount of information on these compounds in health and
disease. It has become apparent that elevations in these lipids occur in
several lysosomal glycosphingolipidoses and that these can be exploited
for diagnostic purposes [6]. Lyso-GSLs are more amphiphilic and water
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their presence in the circulation and in urine. In patients suffering
from the lysosomal disorders FD and GD, marked increases in
globotriaosylsphingosine (lysoGb3) and glucosylsphingosine (GlcSph),
respectively, are demonstrable in plasma as well as in urine [7–11].
To assess the speciﬁcity of abnormalities in lyso-GSLs, we compara-
tively determined the concentrations of GlcSph and lysoGb3, and corre-
sponding GSLs, in the context of primary deﬁciencies in lysosomal
glycosidases involved in GSL catabolism as well as in the context of a
more generalized lysosomal dysfunction as in NPC. We investigated
Twitcher mice deﬁcient in galactocerebrosidase (GALC, EC 3.2.1.46), a
model for Krabbe disease [12,13];mice lacking LIMP-2, deﬁcient in lyso-
somal glucocerebrosidase (GBA, EC 3.2.1.45) due to anomalous
targeting of the enzyme to lysosomes, a model for Action Myoclonus
Renal Failure syndrome (AMRF) [14,15]; genetically modiﬁed mice
with an inducible GBA deﬁciency in the white blood cell lineage, a
model for type 1 GD [16]; and mice deﬁcient in α-galactosidase A
(GLA, EC 3.2.1.22) due to the knock out of theGLA gene, amodel for clas-
sic FD [17]. Additionally, we investigated twomousemodels of NPC dis-
ease: the Npc1nih mouse characterized by a null allele due to an early
truncation of the NPC1 protein andmimicking the severe early infantile
form of the disease [18], and the Npc1nmf164 mouse expressing NPC1
protein with a point mutation leading to partial loss of the protein's
functionality and a more benign phenotype [19]. In our study we
employed LC–MS/MS and internal 13C5-isotope labeled lyso-GSLs stan-
dards for the sensitive quantiﬁcation of these structures [10,20,21].
We here report on the characteristic abnormalities in lyso-GSLs in the
various lysosomal storage disorders (LSDs) mouse models studied.
The signiﬁcance for human disease is illustrated by the demonstration
of increased GlcSph in plasma of NPC patients.
2. Materials and methods
2.1. Animals
The generation of the GD1 mouse model (Gbatm1Karl/tm1KarlTg(Mx1-
cre)1Cgn/0) with inducible knock down of GBA in the white blood cell
lineage has been described previously [16,22]. These mice were main-
tained in individually ventilated cages with ad libitum food and water
at the animal facility in Lund University Biomedical Center. Breeding
and experimental procedures were approved by the Committee for
Animal Ethics in Malmö/Lund, Sweden. Male Fabry Gla−/0 mice and
wild-type (wt) littermates were generated by crossing heterozygous
Gla+/− female mice with wtmales. Pups were genotyped as previously
described [17]. Glatm1Kul (stock number 003535) and Ldlrtm1Her (stock
number 002207) were purchased from The Jackson Laboratory (Bar
Harbor, USA).Npc1nih/nih andmiceNpc1nmf164, alongwithwt littermates
(Npc1+/+),were generated by crossingNpc1+/nih orNpc1+/nmf164males
and females in-house. The heterozygous BALB/c Nctr-Npc1m1N/J mice
(stock number 003092) and C57BL/6J-Npc1nmf164/J (stock number
004817) were obtained from The Jackson Laboratory (Bar Harbor,
USA). Mouse pups were genotyped according to published protocols
[18,19]. Breeding pairs of LIMP2 deﬁcient mice were kindly provided
by Prof. Paul Saftig (Kiel, Germany). Homozygous wt animals (Limp2+/
+) and homozygous knockout animals (Limp2−/−) were generated by
crossing heterozygous (Limp2+/−) mice. Genotype was determined by
PCR using genomic DNA [15]. Twitcher mice (twi/twi) alongwithwt lit-
termates were generated by crossing heterozygous (+/twi) mice in-
house. The heterozygous C57BL/6J B6.CE-Galctwi/J mice (stock number
000845) were obtained from The Jackson Laboratory (Bar Harbor,
USA). Mouse pups were genotyped as previously described [13]. Mice
(3 weeks old) received the rodent AM-II diet (Arie Blok Diervoeders,
Woerden, The Netherlands). LDLr deﬁcient and Fabry mice in the
cross-in studywere fed a western-type of diet (casein 20%, cacao butter
15%, corn oil 1%, cholesterol 0,25%; Code: 4021.06, Arie Blok
Diervoeders, Woerden, The Netherlands) for four weeks. The micewere housed at the Institute Animal Core Facility in a temperature-
and humidity-controlled room with a 12-h light/dark cycle and given
free access to food and water ad libitum. All animal protocols were
approved by the Institutional Animal Welfare Committee of the Aca-
demic Medical Center of Amsterdam in The Netherlands (DBC3021,
DBC101698, DBC102873, DBC100757-125 and DBC17AC). All animal
studies were performed in accordance with the European Communities
Council Directive of 24 November 1986 (86/609/EEC). Mice were
sacriﬁced at indicated age according to protocol, beingﬁrst anesthetized
with a dose of Hypnorm (0.315 mg/mL phenyl citrate and 10 mg/mL
ﬂuanisone) and Dormicum (5 mg/mL midazolam) according to their
weight. The administered dose was 80 μL/10 g bodyweight. Anesthe-
tized animals were sacriﬁced by cervical dislocation. Organs were col-
lected by surgery and rinsed with PBS. All samples and tissues
collected were stored at−80 °C prior to further analysis. Later, homog-
enates for lipid analysis were prepared, in 25mMpotassium phosphate
buffer, pH 6.5, supplemented with 0.1% (v/v) Triton X-100 and protease
inhibitors, using a tissue homogenizer (FastPrep®24).
2.2. Lipid measurements
GSLs and lyso-GSLs bases were measured with small modiﬁcations
to earlier described methods [10,21,23]. Brieﬂy, following extraction
from biological samples neutral GSLs (ceramide, glucosylceramide,
lactosylceramide and globotriaosylceramide) were determined by an
HPLC-based procedure following microwave-assisted de-acylation of
lipids and derivatization with o-phthaldialdehyde [23]. The lyso-GSLs
lysoGb3 and GlcSph were quantiﬁed with speciﬁc LC–MS/MS methods
employing appropriate internal (isotope labeled) standards [10,21].
Lipid levels are expressed per gram of wet weight in the case of tissues
or per mL in the case of plasma.
2.3. Glycosphingolipid digestion
The methods used to quantify GSLs and lyso-GSLs do not allow dis-
tinction between lipids differing only in terminal glucose or galactose
moiety as those are incompletely separated by reverse-phase chroma-
tography. Therefore we refer to the lipid species as glycosylated (gly)
whenever the exact identity is not established. When mentioned, lipid
samples were digested with recombinant GBA (rGBA, Cerezyme,
Genzyme) to determine the percentage of glucosylated lipid species.
For digestion 5 μL of pure rGBA solution was mixed in 200 μL of
McIlvaine buffer 150mMpH5.2 and used to dissolve the dried lipid pel-
let and incubated overnight at 37 °C.
2.4. Patients
EDTA plasma samples of 17 NPC patients and 9 NPC carriers were
collected prior to therapy at the Unidad de Investigación Translacional
in Zaragoza. The status of affected or carrier of NPC disease was deter-
mined after the exonic sequencing of NPC1 and NPC2 genes. Filipin
stainings of ﬁbroblasts were conducted to complete the diagnosis. Plas-
ma samples of 37 male and 42 female control subjects were collected at
the Academic Medical Center according to protocol. Plasma samples
were stored frozen at−20 °C until further use.
2.5. Ethics statement
Awritten informed consent was obtained from each patient or their
guardian. The study protocol was approved by the Ethics Committee for
Clinical Investigation of Aragon (CEICA) in Spain. A written informed
consent was also obtained from each healthy volunteer. The study was
carried out in accordance with the ethical standards of the Declaration
of Helsinki.
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3.1. Abnormalities in tissues of LSD mouse models
The concentrations of GSLs (ceramide [Cer], glycosylceramide
[GlyCer], lactosylceramide [LacCer] and globotriaosylceramide [Gb3])
and of the lyso-GSLs (glycosylsphingosine (GlySph) and lysoGb3)
were ﬁrstly determined for liver (Table 1) and spleen (Table 2) of
male Fabry (Gla−/0) mice, inducible Gaucher mice (Gbatm1Karl/
tm1KarlTg(Mx1-cre)1Cgn/0), GBA-deﬁcient Limp2−/− and Krabbe
(Galc−/−) mice. As reference values, the samemeasurements were per-
formed inwtmice with different backgrounds (BALB/c (Bc) and C57BL/
6 (B6)) and included in the tables presented here. For statistical and fold
difference analysis the mice were compared to the respective wt age-
matched littermates.
Themale FDmice, completely deﬁcient inα-galactosidase A activity,
show elevated hepatic and splenic Gb3 (15-fold and 35-fold, respective-
ly), a ﬁnding not made for the other LSD models studied (Tables 1 & 2).
Likewise, lysoGb3 is very clearly and speciﬁcally elevated in both tissues
of FDmice: 430-fold in liver and 2200-fold increased in spleen (Tables 1
& 2). No signiﬁcant changes in any of the other examined sphingolipids
and sphingoid bases were detected in FD mice. In contrast, GBA-
deﬁcient Limp2−/− mice show near normal GlyCer in combination
with elevated GlySph in both tissues (Tables 1 & 2). Inducible GD type
1 (GD1, Gbatm1Karl/tm1KarlTg(Mx1-cre)1Cgn/0) mice present a 10–20
fold larger accumulation of both GlyCer and GlySph than the GBA-
deﬁcient Limp2−/− animals. Of note, the GlyCer and GlcSph levels in
GD1mice varied considerably between animals, likely due to individual
differences in induction of GBA knock down. Galc−/−mice at end-stage
show amarked elevation in GlySph in liver and spleen (Tables 1 & 2). In
vitro digestion of GlySph with rGBA revealed that in both tissues only
10% is GlcSph and the remainder is most likely galactosylsphingosine
(GalSph), also known as psychosine. No prominent increase in GlyCer
was observed in the GALC-deﬁcient liver and spleen, likely due the
fact that the majority of GlyCer in these organs is GlcCer.
Next, we analyzed liver and spleen of NPC – Npc1nih and Npc1nmf164
–mice. Npc1nih animals are known to have a partial secondary deﬁcien-
cy in GBA and acid sphingomyelinase [24,25]. We report for the ﬁrst
time that GBA activity is also reduced in Npc1nmf164 mice (see Supple-
mental Fig. 2). We used materials from NPC mice sacriﬁced at end-
stage, when the characteristic prominent increases in lysosomal choles-
terol in tissues occur (Marques et al. unpublished). Both GlyCer and
GlySph were found to be extremely elevated in liver and spleen of
both NPC models, comparably to inducible GD1 mice (Tables 1 & 2).
Digestion with rGBA showed that the vast majority (N95%) of GlyCer
is GlcCer and that of GlySph is GlcSph (not shown). More modest, but
highly signiﬁcant, increases in LacCer, Gb3 and Cer levels were also ob-
served in the liver and spleen of both NPC models.
3.2. Abnormalities in heart and kidney of Fabry mice
We investigated in more detail male FD mice by analysis of lipids in
their heart and kidney, two affected organs in the disease (Table 3).Table 1
Overview of the concentrations of major GSLs and lyso-GSLs in liver of variousmouse LSDmod
(nmol/g wet weight) and lyso-GSLs (pmol/g wet weight) in the liver. As referencewtmice of th
(n = 3–6).
Model Wt B6 Wt Bc Fabry GD1
Age (wk) 16 12 20 10–12
GlySph 13.33 ± 5.77 15.13 ± 1.03 24.17 ± 0.90 4111.8 ± 5106.7
LysoGb3 14.23 ± 1.45 7.46 ± 0.71 7868.4 ± 2817.6 14.75 ± 1.81
GlyCer 33.1 ± 3.2 34.2 ± 5.2 38.7 ± 3.9 289.4 ± 465.6
Gb3 2.2 ± 0.5 1.8 ± 0.9 352.7 ± 125.8 1.1 ± 0.5
LacCer 14.2 ± 1.4 29.5 ± 9.9 11.3 ± 1.3 5.0 ± 3.2
Cer 150.0 ± 4.0 338.1 ± 93.4 384.4 ± 29.8 91.9 ± 21.7Corresponding wt littermates, also sacriﬁced at 20 weeks of age, were
analyzed. As observed in liver and spleen, FD mouse heart and kidney
show a clear increase of Gb3 in combinationwith a prominent elevation
of lysoGb3 concentration. The FD heart accumulates more Gb3 (~20-
fold increase compared to wt) than the kidneys (~5-fold increase com-
pared to wt), while the FD kidneys store more lysoGb3 (~200-fold in-
crease compared to wt) than the heart (~120-fold increase compared
to wt) (Table 3).
3.3. Abnormalities in the plasma of LSD mouse models
We then compared the levels of lipids in plasma samples obtained
from the various disease models (Table 4). None of the quantiﬁed
glycosphingolipids (Cer, GlyCer, LacCer and Gb3) was signiﬁcantly in-
creased in any of the examined murine LSD models, except for a signif-
icant ~17-fold increased Gb3 in FD mice plasma. In sharp contrast,
marked abnormalities were detected in plasma concentrations of lyso-
GSLs in the LSD models. For instance, plasma of male FD mice showed
~200-fold elevated lysoGb3. In the case of GBA-deﬁcient Limp2−/−
mice, plasma GlySph was 4-fold increased, but no clear abnormalities
in other lyso-GSLs are detected. Insufﬁcient plasma of GD1 mice was
available for complete lipid analysis following that of GlcSph which
was found to be 170-fold elevated [26]. In the case of Krabbemice, plas-
ma galactosylsphingosine (GalSph, more than 90% of total GlySph) was
about ~12-fold increased, but other lyso-GSLs appeared normal. Whilst
in the lysosomal enzymopathy models elevations in lyso-GSLs coincid-
ed with the primary GSL substrate, the picture for plasma of both NPC
mouse models is different. In these animals a signiﬁcant (2–4 fold) in-
crease in plasma GlySph levels was observed in conjunctionwith signif-
icantly reduced lysoGb3 levels compared to age-matched wt controls
(Table 4). Of note, the abnormality in plasma GlySph matches that ob-
served in Limp2−/−mice deﬁcient in lysosomal GBA. The speciﬁcity of
plasma lyso-GSLs abnormalities is also illustrated in Fig. 1 showing the
relative increase in plasma GlySph and lysoGb3 in the various LSD mu-
rine models.
3.4. Source of elevated lysoGb3 in tissues of Fabry mice
The origin of the increased lysoGb3 in Fabrymouse tissues is unclear
since we cannot discriminate a priori between endogenous production
in a tissue, uptake of elevated lysoGb3 from the circulation or active for-
mation of lysoGb3 from endocytosed lipoprotein-associated Gb3. To
distinguish between these possibilities we exacerbated GSL stress
from the circulation. For this purpose, FD mice were crossed with
Ldlr−/− mice showing impaired uptake of GSL-rich lipoprotein LDL
and therefore very high plasma GSL levels when fed a lipid-rich
western-type diet [27]. As shown in Fig. 2, male double-knockout
Gla−/0/Ldlr−/− mice on a western-type diet show elevated GSL levels
in their plasma. For example, plasma Gb3 in the Gla−/0/Ldlr−/−mice is
even 3.5-fold higher compared to regular Gla−/0 FD mice that already
show a 2.5-fold increase compared to Ldlr−/− mice (Fig. 2). Similar
observations were made for lysoGb3, being 3-fold increased in maleels. Indicated is the age at which the animals were sacriﬁced and the concentration of GSLs
e BALB/c (Bc) and C57BL/6 (B6) background are shown. Data represent the mean ± S.D.
Limp2−/− Galc−/− Npc1nih Npc1nmf
16 5 12 16
254.30 ± 139.84 402.20 ± 6.84 3121.2 ± 453.4 4786.0 ± 1735.0
5.58 ± 3.10 11.17 ± 1.46 13.56 ± 0.85 20.46 ± 3.07
23.4 ± 13.0 35.7 ± 9.7 419.4 ± 147.0 354.5 ± 80.7
4.0 ± 3.3 1.7 ± 0.2 12.9 ± 4.3 18.4 ± 1.7
5.8 ± 2.6 7.0 ± 1.6 248.6 ± 73.3 170.4 ± 26.2
111.5 ± 40.9 134.5 ± 4.3 633.4 ± 203.3 438.7 ± 44.7
Table 2
Overviewof the concentrations ofmajor GSLs and lyso-GSLs in spleen of variousmouse LSDmodels. Indicated is the age atwhich the animalswere sacriﬁced and the concentration of GSLs
(nmol/g wet weight) and lyso-GSLs (pmol/g wet weight) in the spleen. As referencewtmice of the BALB/c (Bc) and C57BL/6 (B6) background are shown. Data represent themean± S.D.
(n = 3–6).
Model Wt B6 Wt Bc Fabry GD1 Limp2−/− Galc−/− Npc1nih Npc1nmf
Age (wk) 16 12 20 10–12 16 5 12 16
GlySph 23.3 ± 5.77 35.7 ± 14.6 60.28 ± 23.93 17,532.5 ± 9023.9 399.98 ± 143.72 254.10 ± 28.36 1719.9 ± 222.6 1682.0 ± 262.0
LysoGb3 6.20 ± 1.38 4.69 ± 2.1 11,157.3 ± 5664.9 6.88 ± 1.33 1.70 ± 0.34 2.53 ± 1.03 30.17 ± 2.40 27.18 ± 5.41
GlyCer 133.1 ± 11.9 89.1 ± 9.2 381.9 ± 30.7 1030.0 ± 1397.5 73.8 ± 6.6 132.0 ± 6.1 348.0 ± 83.2 336.5 ± 41.7
Gb3 46.2 ± 5.8 51.0 ± 4.4 1417.9 ± 245.6 24.9 ± 9.3 9.8 ± 5.5 43.0 ± 3.5 85.5 ± 26.4 83.8 ± 12.9
LacCer 17.7 ± 1.4 13.3 ± 3.5 40.9 ± 42.2 13.3 ± 2.6 6.1 ± 2.0 13.2 ± 0.9 164.0 ± 40.0 116.5 ± 17.3
Cer 104.6 ± 8.5 71.6 ± 3.8 125.4 ± 13.8 99.5 ± 16.7 70.1 ± 6.5 89.0 ± 7.2 161.1 ± 15.4 205.9 ± 13.4
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as compared to Ldlr−/−mice (Fig. 2).
Analysis of tissues revealed that despite the extremely high plasma
Gb3 and lysoGb3 in male Gla−/0/Ldlr−/− mice, the concentration of
Gb3 or lysoGb3, was similar in their liver, spleen, heart and kidney to
that of regularmale Fabrymice (see Fig. 2 and Supplemental Fig. 3). Ap-
parently, the chronic exposure to high levels of circulating lyso-GSLs
contributed little to the accumulation of the same lipids in the various
tissues analyzed, suggesting that these have largely an endogenous
production.
3.5. Accumulation of sphingoid bases in Niemann–Pick type C patients
The ﬁndings made with themurine LSDmodels are recapitulated by
analysis of plasma samples from patients suffering from FD, GD and
AMRF. We previously documented that plasma lysoGb3 is 200-fold in-
creased in male classic FD patients [21,28]. Likewise, plasma GlcSph
has been found to be on average 300-fold increased in patients suffering
from GD1 [8,10]. Finally, in the two AMRF patients examined, plasma
GlySph was found to be 8-fold elevated [29]. These ﬁndings prompted
us to comparatively examine plasma obtained from NPC patients.
The plasma concentrations of Cer, LacCer, and Gb3 were not signiﬁ-
cantly abnormal in NPC patients (n = 17, median age = 42, range 2–
68 years) or carriers for the disease (n = 9, age = 53, range 28–
59 years) compared to healthy control individuals (n = 79, age = 38,
range 20–65 years). Of note, plasma GlyCer in the NPC patients showed
a trend ofminor elevation, however the differencewith normal subjects
did not reach signiﬁcance. As in themousemodels, analysis of lyso-GSLs
did reveal much clearer differences between NPC patients and healthy
subjects. Plasma lysoGb3 in NPC patients (mean 0.34, range 0.23–
0.54 pmol/mL) was within the lower range of the controls (mean 0.39,
range 0.22–0.64 pmol/mL, Fig. 3). A signiﬁcant difference was observed
for plasma GlySph, being on average higher in NPC patients (mean 1.76,
range 0.72–4.49 pmol/mL) with some overlap with the upper control
range (mean 0.78, range 0.15–2.50 pmol/mL).
Oxysterols have been documented as a sensitive biomarker for NPC
[30]. To compare the noted abnormality in plasma GlySph, oxysterolsTable 3
Overview of the concentrations of major GSLs and lyso-GSLs in heart and kidney of FD
mouse model.
Fabry male mice andwt littermates were sacriﬁced at 20 weeks of age. The concentration
of GSLs and lyso-GSLs in the kidney and heart is expressed in nmol/g wet weight and
pmol/g wet weight, respectively. Data represent the mean ± S.D. (n = 3).
Organ Heart Kidney
Model Wt Fabry Wt Fabry
GlySph 3.7 ± 3.1 1.2 ± 2.1 33.6 ± 4.4 26.2 ± 1.5
LysoGb3 4.2 ± 0.8 496.83 ± 87.3 8.1 ± 3.1 1568.3 ± 76.6
GlyCer 108.2 ± 38.7 97.4 ± 12.4 51.5 ± 5.4 54.4 ± 0.3
Gb3 60.7 ± 3.7 1173.4 ± 109.8 114.3 ± 32.0 559.8 ± 58.5
LacCer Tracea Tracea 7.5 ± 0.6 15.7 ± 1.6
Cer 118.9 ± 7.8 118.1 ± 4.8 250.7 ± 3.7 296.2 ± 17.4
a Discernable signal but below limit of quantiﬁcation (b10× noise).were determined in the same plasma samples. Plasma oxysterols were
found to be increased (mean 343, range 34–1157 ng/mL) compared to
controls (b102.8 ng/mL) [31]. The abnormality of plasma oxysterols in
the patients was more prominent than the deviation in GlySph levels.
However, no correlation was observed between incremental oxysterols
and GlySph in NPC patients (Fig. 4).
4. Discussion
Our comparative quantitative investigation of GSLs and correspond-
ing lyso-GSLs inmousemodels of deﬁciencies ofα-galactosidase A, GBA
and GALC recapitulates earlier observations in patients suffering from
FD, GD1/AMRF and Krabbe disease, respectively [7,22,29,32]. The
noted abnormalities in GSLs and lyso-GSLs and their speciﬁcity for the
various disorders merit discussion.
As in male patients, deﬁciency of α-galactosidase A in male mice
leads to increased levels of the primary substrate Gb3 in several tissues
such as liver (15-fold), spleen (35-fold), heart (20-fold) and kidney (5-
fold). Gb3 is also considerably elevated in plasma (30-fold). A far more
striking abnormality is seen for the lyso-GSL of Gb3, lysoGb3. In plasma
of Fabrymice lysoGb3 exceeds normal levels 190-fold. LysoGb3 concen-
trations are increased 430-fold in liver, 2200-fold in the spleen, 120-fold
in heart and 200-fold in kidney. The very high lysoGb3 levels of spleen
are likely explained by the high rate of degradation by splenic macro-
phages of senescent blood cells rich in globosides. Earlier we observed
that lipid-laden macrophages occur in Fabry patients as reﬂected by in-
creased plasma chitotriosidase [33]. Of interest, sphingolipid abnormal-
ities in this animal model are restricted to Gb3 and lysoGb3. No
abnormalities are demonstrable for GlyCer, LacCer or ceramide. Like-
wise, GlySph is normal in the investigated Fabry animals. Of note, GlcCer
is not decreased in Fabry mice suggesting that there is no feedback on
GSL biosynthesis to avoid ongoing Gb3 accumulation.
FD is a complex multi-organ disease with broad clinical manifesta-
tions such as cardiomyopathy, renal failure, pain and peripheral neurop-
athy [34]. We, and others, looked for correlations between plasma
lysoGb3 levels and various disease manifestations. Although patients
with higher lysoGb3 levels showed a trend tomore pronounced disease
manifestations, no signiﬁcant correlation of plasma lysoGb3 and speciﬁc
symptoms was noted except for pain [35,36]. Very recently Choi and
colleagues presented experimental evidence for a direct effect of
lysoGb3 on sensory neurons [37]. It was reported that plantar adminis-
tration of lysoGb3 induces mechanical allodynia in mice. Sensory neu-
rons expressing nociceptor markers showed enhanced peak current
densities of voltage-dependent Ca2+ channels in the presence of 1 μM
lysoGb3, close to concentrations occurring in plasmaofmale FDpatients
[7]. The authors concluded that lysoGb3 plays a direct role in the sensi-
tization of peripheral nociceptive neurons. At present a direct role for
lysoGb3 in the pathophysiology of heart and kidney in Fabry patients
has not been demonstrated. Noteworthy however, in connection to
renal disease, is the demonstration of pro-ﬁbrotic action of lysoGb3 in
experimental models [38,39].
Our ﬁndings regarding lyso-GSLs and lipids in the mouse models of
GBA deﬁciency are consistent with reports for Gaucher patients and
Table 4
Overviewof the concentrations ofmajor GSLs and lyso-GSLs in plasma of variousmouse LSDmodels. Indicated is the age at which the animals were sacriﬁced and the concentration of the
lipids in plasma in nmol/mL and those of lyso-GSLs in pmol/mL. As referencewtmice of the BALB/c (Bc) and C57BL/6 (B6) background are shown. Data represent themean± S.D. (n=3–
5).
Model Wt B6 Wt Bc Fabry GD1 [26] Limp2−/− Galc−/− Npc1nih Npc1nmf
Age (wk) 16 12 20 20–68 16 5 12 16
GlySph 0.89 ± 0.09 0.50 ± 0.07 0.16 ± 0.11 65.88 ± 38.69 3.56 ± 1.73 11.83 ± 1.01 1.56 ± 0.62 4.04 ± 0.57
LysoGb3 1.21 ± 0.36 0.69 ± 0.13 571.15 ± 22.91 N.A. 0.90 ± 0.66 0.67 ± 0.49 0.15 ± 0.03 0.33 ± 0.17
GlyCer 3.05 ± 0.55 1.94 ± 0.18 3.14 ± 0.01 4.30 ± 1.87 1.80 ± 1.08 2.41 ± 0.39 1.73 ± 0.53 2.79 ± 0.92
Gb3 0.24 ± 0.02 0.28 ± 0.04 4.11 ± 0.01 N.A. 0.42 ± 0.28 Tracea 0.14 ± 0.05 0.18 ± 0.02
LacCer 0.19 ± 0.04 0.27 ± 0.05 Tracea N.A. 0.34 ± 0.26 Tracea 0.30 ± 0.04 0.17 ± 0.01
Cer 2.15 ± 0.54 2.43 ± 0.51 2.21 ± 0.01 2.97 ± 1.35 1.22 ± 0.33 1.36 ± 0.12 2.13 ± 0.56 1.59 ± 0.19
a Discernable signal but below limit of quantiﬁcation (b10× noise). N.A. — not available.
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the differences noted between mice with induced GBA knock-down in
white blood cells and mice lacking LIMP2, the transporter of GBA to ly-
sosomes [15,16,22,41]. In the latter animals GBA is extremely low in
most cell types, but not inmacrophages likely due to re-uptake of faulty
secreted GBA [29,42] (Gaspar et al. unpublished). Our ﬁndings with
GBA-deﬁcient Limp2−/−mice suggest that most cell types despite
major deﬁciency in GBA successfully prevent GlcCer accumulation and
apparently their macrophages have sufﬁcient residual GBA to limit
GlcCer storage by transforming it to GlcSph. This however does not
hold for GBA-deﬁcient macrophages in GD1 mice. Here prominent
GlcCer accumulation occurs, accompanied by elevated plasma GlcSph.
Thus, in theGBA-deﬁcientmacrophages of Gaucher patients the loading
of lysosomeswith GSLs surpasses the capacity to re-route accumulating
GlcCer to GlcSph. Another example of adaptation is presented bywt and
Fabry mice in which deﬁciency of the LDL receptor is introduced. Both
these animals develop upon high fat feeding very high plasma concen-
trations of various GSLs. The mice also show a modest increase in plas-
ma GlcSph which might point to an adaptive attempt to prevent
lysosomal GlcCer storage.
The increased tissue and plasma GlcSph levels in GBA-deﬁcient
Limp2−/− mice suggest that in tissues GlcCer is actively deacylated to
GlcSph, which subsequently reaches the circulation. Indeed, we earlier
presented evidence that GBA-deﬁcient cells upon pharmacological inhi-
bition of GBA start to accumulate GlcCer and concomitantly formGlcSph
[8], most likely due to the action of ASAH1 (Ferraz et al. unpublished). In
experimental cell models GlcSph has been found to be potentially toxic
by causing lysis of red blood cells, impairing cell ﬁssion during cytokine-
sis, damaging speciﬁc neurons, hampering growth, impairing osteo-
blasts, and promoting inﬂammation via activation of phospholipase A2
[43,44]. The concentrations of GlcSph required for the observed toxic
effects exceed those measured in plasma of GD patients. Consequently,
it remains unclearwhether the GlcSph contributes to the symptoms ob-
served in GD patients, such as occurrence of hemolysis, multinucleated
macrophages, neuropathology, growth retardation, bone deteriorationFig. 1. Relative changes in lyso-GSLs in plasma of LSDmouse models. Levels of GlySph and
lysoGb3 in the plasma of LSDmouse models relative to respectivewt littermates. # Levels
of lysoGb3 on plasma of GD1 mice are not available.and chronic low grade inﬂammation [6]. Recent investigations by
Cox and coworkers have revealed an intriguing correlation between
the occurrence of lymphoma in Gbatm1Karl/tm1KarlTg(Mx1-cre)1Cgn/0
mice and GlcSph levels [26,45]. Currently a direct role for elevated
GlcSph in the symptomatology of GD has not yet been unequivocally
demonstrated.
The noted elevation in plasma GalSph in galactocerebrosidase deﬁ-
cient Twitcher mice is similar to the reported elevation of GalSph in
Krabbe patient materials [46]. A direct pathological role for GalSph has
been proposed for the neuropathology of Krabbe disease. GalSph trig-
gers apoptosis of oligodendrocytes and Schwann cells by disrupting
lipid rafts in myelinating glia [47,48]. This results in demyelination
affecting both the central and peripheral nervous systems [49,50]. How-
ever, there is still discussionwhether axonopathy is secondary to demy-
elination or if is directly caused by the GalSph accumulation in Krabbe
neurons [51].
Besides lysosomal enzymopathies, we included in our investigation
NPC disease mice with a more generalized lysosomal dysfunction. The
investigated Npc1nih mouse strain is a spontaneous model of NPC dis-
ease. The animals present a null allele and are thus fully deﬁcient in
NPC1 protein [18,24]. This lysosomal transmembrane protein, together
with the soluble NPC2 protein, is responsible for the efﬂux of free
(unesteriﬁed) cholesterol from the late-endosomal/lysosomal compart-
ment to the cytosol [52]. Deﬁciency in NPC1 protein leads to a massive
accumulation of cholesterol in visceral organs of the mice. We and
others have shown that, at end-stage, hepatic cholesterol levels are
10-fold higher in Npc1nih mice compared to wt littermates [53,54]
(Marques et al. unpublished). The extreme sterol accumulation in lyso-
somes is thought to impair the activity of other lysosomal hydrolases
[24,25,55]. GBA activity, for example, is reduced to half in the liver of
Npc1nih mice [24] and Npc1nmf164 late-onset mice (see Supplemental
Fig. 2) for reasons not fully elucidated yet. The deﬁcient GBA activity
in NPC lysosomes leads to a prominent accumulation of its glucosylated
substrate: GlcCer. In fact, the observed accumulation of GlcCer in liver of
both studied NPC mouse strains even surpasses levels detected in the
livers of GD1 mice with an induced GBA deﬁciency in the white blood
cell lineage (see Table 1). Concomitantly GlcSph is elevated in Npc1nih
livers, but to a lesser extent possibly due to partly impaired acid
ceramidase activity. Increased levels of other sphingolipids such as
Cer, LacCer and Gb3 also occur in liver of the studied Npc1nih mice. As
earlier observed by others [24,56], we noted elevated gangliosides in
tissues of NPC mice (not shown). Accumulation of sphingomyelin in
Npc1nih liver has been extensively documented [24,54,56]. Npc1nmf164
mice present amilder course of NPC disease but at end-stage show sim-
ilar lipid abnormalities as Npc1nih mice.
Recently increased levels of GlcSph have been reported in NPC pa-
tient cohorts [57,58]. Our investigation conﬁrms that the lyso-GSL
tends to be elevated in the majority of patients analyzed. Recently, ele-
vations in phosphorylcholinesphingosine (deacylated sphingomyelin,
lysoSM) and in the isoform lysoSM-509 were described in plasma of
NPC patients [57,59]. Plasma oxysterols have earlier been validated as
sensitive biomarker for NPC [30,60]. We measured in the same NPC
Fig. 2. LDLr deﬁciency in Fabry mice on a western-type diet exacerbates lipid abnormalities in plasma but not in liver. Upper panel: Plasma GSL (Gb3 and GlyCer) and lyso-GSL (lysoGb3
and GlySph) in male Gla−/0 (Fabry), Ldlr−/−, and combined Gla−/0/Ldlr−/− mice receiving western type diet. Lower panel: Liver lipid levels as above. Data were analyzed by Mann–
Whitney u-test: * P b 0.05; ** P b 0.01.
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found to be increased (mean 343, range 34–1157 ng/mL) as compared
to controls (b102.8 ng/mL). The abnormality in plasma oxysterols in
NPC patients was far more prominent than the one observed in GlySph
and no correlation between the two was observed. From these ﬁndings
it may be concluded that for conﬁrmation of the NPC diagnosis demon-
stration of abnormal plasma oxysterols should be preferred over that of
GlcSph.
In summary, our comparative LC–MS/MS-based analysis of GlySph
and lysoGb3 in tissues and plasma of mouse LSD models withFig. 3. GSLs and lyso-GSLs in NPC patients. Plasma levels of GSLs and lyso-GSLs in healthy volun
NPC patients (n = 17). Data were analyzed using the Mann–Whitney u test.deﬁciencies in GLA, GBA and GALC revealed speciﬁc abnormalities coin-
ciding with the GSL substrate of the deﬁcient glycosidases. Interestingly
Limp2−/− mice are an exception to this rule and seem to almost
completely avoid GlcCer accumulation. In two distinct mouse models
of NPC (Npc1nih and Npc1nmf164) accumulation of several neutral GSLs
was observed in tissues and concomitantly elevations in plasma GlySph
were detected. This ﬁnding was conﬁrmed by the noted increase in
GlySph in plasma of NPC patients. Our study points out that detection
of lyso-GSLs may assist in diagnosis of glycosphingolipidoses, however
care should be taken to establish the speciﬁcity of noted abnormalitiesteers (n = 79), carriers of one knownmutation on the Npc1 gene (n= 9) and conﬁrmed
Fig. 4. Correlation between GlySph and Oxysterols plasma levels in diagnosed NPC
patients.
192 M.J. Ferraz et al. / Molecular Genetics and Metabolism 117 (2016) 186–193by rigorous documentation of plasma lyso-GSL in other conditions with
impaired lysosome function, for genetic reasons and possibly as well
when induced by chronic exposure to lysosomotropic drugs.
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